A recent study demonstrated that FTO inhibition with FB23-2 enhances the efficacy of radiotherapy in EBV-positive radioresistant nasopharyngeal carcinoma cells and tumors (23). This evidence concerns the gene FTO and nasopharyngeal carcinoma.